HIV-1-infection
Conditions
Brief summary
The objective of this grant is to create and test a mobile app to support ART adherence among HIV+ African American adults.
Detailed description
The Phase II project will enhance the existing (Phase 1) mobile intervention by offering: 1) a two-way communication capability through which participants can: i) indicate pill taken in response to pill reminders, and ii) receive a positive visual icon as behavioral-economics based reinforcement for pill taken responses; 2) pharmacist counseling and medication support; and, 3) the addition of educational and motivational text messages. Overall aims are to: 1) expand mhealth intervention to incorporate new Phase II features; 2) evaluate effectiveness in an RCT of HIV+ African Americans; and 3) prepare marketing and commercialization plans. Our long-term goal is to increase ART medication adherence, thus decreasing health disparities, among HIV+, African-Americans.
Interventions
BEHAVIORALOn the Dot Mobile app
On the Dot is a mobile app to support HIV medication adherence. The mobile app is linked to a clinician portal through which participants can receive adherence support.
Sponsors
Prisma Health
Environment and Health Group, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Masking description
Investigators and participants were aware of which group participants were randomly assigned to.
Intervention model description
Randomized controlled trial in which participants were randomly assigned to intervention group or control group.
Eligibility
Sex/Gender
ALL
Age
30 Years to No maximum
Healthy volunteers
No
Inclusion criteria
(a) self-identify as African American, (b) age 30 or older, (c) HIV positive (d) currently on ART (e) report having problems with, and interest in improving their ART adherence (f) own a smartphone (g) report English as their primary language \-
Exclusion criteria
(a) not self-identified as African American, (b) under age 30 (c) HIV negative (d) not currently on ART (e) do not report having problems with, or interest in, improving their ART adherence (f) do not own a smartphone (g) do not report English as a primary language and (h) participating in another research study or clinical trial (i) receiving care at non-participating site and, (j) dementia diagnosis. \-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Self-reported ART medication adherence | 90 days | Adherence was assessed using a 3-item self-report measure examining ART use in the prior 7 days, a time period, which is considered a reliable indictor of overall adherence (Bianco et al., 2010; Kleeburger et al., 2001; Segeral et al., 2010; Spire et al. 2008). The measure consists of a yes or no response to each of the following three questions: (i) did you miss any ART doses during the last four days?, (ii) Were you late for any of your intakes by more than two hours during the last four days?, and (iii) did you miss any ART doses last week-end? |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| HIV medication adherence self efficacy | 90 days | HIV treatment self-efficacy was assessed using the 17-item self-efficacy belief subscale of the modified HIV Medication Taking Self-Efficacy Scale. |
| Stress Burden | 90 days | Stress burden will be assessed using the Perceived Stress Scale (Cohen et al., 1983), a well-validated instrument used with diverse populations. |
Countries
United States
Outcome results
None listed